Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as APG -2449
APG-2449 · 1 trial · 5 indications
To determine the maximum tolerated dose (MTD) of APG-2449 in subjects with advanced solid tumors
To determine the tentative recommended Phase 2 dose (RP2D) of APG-2449 in subjects with advanced solid tumors
| Arm | Type | Description |
|---|---|---|
| APG-2449 | EXPERIMENTAL | APG-2449 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 30-40 patient at the MTD/RP2D dose level. |
| Name | Type | Description |
|---|---|---|
| APG-2449 | DRUG | Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle |
Inclusion Criteria: 1. Dose exploration stage: non-small cell lung cancer diagnosed by histology and/or cytology and positive for ALK/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and malignant pleural mesothelioma, esophageal cancer and ovarian cancer. Kind of patients with ...
APG-2449 is an investigational small molecule being studied for the treatment of platinum-resistant recurrent ovarian cancer and advanced solid cancers, including non-small cell lung cancer, esophageal cancer, and malignant pleural mesothelioma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
APG-2449 targets FAK, ALK, and ROS1, which are tyrosine kinases involved in tumor growth and progression. By inhibiting these targets, the drug aims to interfere with cancer cell signaling pathways. This mechanism is being evaluated in early-stage clinical trials for solid tumors.
APG-2449 is being developed by Ascentage Pharma Group International, a biopharmaceutical company listed on the stock exchange under the ticker AAPG. The company is conducting clinical trials for this investigational drug in China.
APG-2449 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing trials are designed to evaluate its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
APG-2449 is being studied in two Phase 1 clinical trials. The first, NCT03917043, evaluates APG-2449 in patients with advanced solid tumors. The second, NCT06687070, studies APG-2449 alone or in combination with PLD in patients with platinum-resistant recurrent ovarian cancer or advanced solid tumors. Both trials are recruiting participants in China.
Yes, APG-2449 is also known as APG-2449. The drug is referred to by this name in clinical trial registries and scientific literature. No other alternative names have been reported for this investigational agent.